Eltrombopag 25 mg ( DrugBank: Eltrombopag )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
60	Aplastic anemia	2

60. Aplastic anemia

---

Clinical trials : 235 /  Drugs : 381 - (DrugBank : 83) / Drug target genes : 44 - Drug target pathways : 160

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03988608 (ClinicalTrials.gov)	December 9, 2019	13/6/2019	Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.	A Non-randomized, Open-label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Chinese Subjects With Refractory or Relapsed Severe Aplastic Anemia	Aplastic Anemia	Drug: Eltrombopag 25 mg	Novartis Pharmaceuticals	NULL	Active, not recruiting	18 Years	N/A	All	20	Phase 2	China
2	NCT02148133 (ClinicalTrials.gov)	July 23, 2014	22/5/2014	A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia	A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia	Cytopaenia	Drug: Eltrombopag 12.5 mg;Drug: Eltrombopag 25 mg	Novartis Pharmaceuticals	NULL	Completed	18 Years	79 Years	All	21	Phase 2	Japan